• Explore /
  • Poster
  • / Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.

Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.

Abstract Poster

Authors

Pierre FENAUX

Pierre Fenaux

Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France

Pierre Fenaux , Valeria Santini , Rami S. Komrokji , Amer Methqal Zeidan , Guillermo Garcia-Manero , Rena Buckstein , Dimana Miteva , Karen Keeperman , Natalia Holot , Jennie Zhang , Christina Hughes , Barbara Rosettani , Aylin Yucel , Uwe Platzbecker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7056)

DOI

10.1200/JCO.2022.40.16_suppl.7056

Abstract #

7056

Poster Bd #

287

Abstract Disclosures

Similar Posters

First Author: Sudipto Mukherjee

First Author: Guillermo Garcia-Manero

First Author: Steven Gilmore

First Author: Adeola Y. Makinde